EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and characterization of a model of mucopolysaccharidosis type IVA for evaluating therapies targeting bone disease

Margherita Berti, Selene Ceriotti, Ludovica Santi, Gaia Alberti, Stefano Beretta, Sara Degl'Innocenti, Cristina Ruatti, Evelyn Oliva Savoia, Raisa Jofra-Hernandez, Giada De Ponti, Simona Bolamperti, Isabella Villa und 23 weitere

Disease Models & Mechanisms · 01.02.2026 · 19 (2)

DOI: 10.1242/dmm.052540 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, online erschienen am 05.03.2026. Verfasst von Margherita Berti und 34 weiteren Autor:innen. Beteiligte Einrichtung: IRCSS San Raffaele Hospital-San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), 20132 Milan, Italy. Hauptthemen laut MEDLINE: Mucopolysaccharidosis IV, Bone Diseases. Die Arbeit nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, NextGenerationEU, Else Kröner-Fresenius-Zentrum für Ernährungsmedizin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucopolysaccharidosis type IVA (MPSIVA) is a lysosomal storage disease (LSD) caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), which causes the accumulation of keratan sulphate (KS) and chondroitin sulphate (CS). Patients with MPSIVA typically present with severe skeletal and joint disorders, which are not addressed by conventional therapies. Currently, no animal model accurately replicates the human disease, hindering the development of novel therapeutic interventions. To overcome this limitation, we established, by CRISPR-Cas9 technology, a Galns−/− mouse model that expresses a non-functional enzyme and accumulates CS and KS in the urine, plasma and distinct tissues, and glycosaminoglycans in the spleen. The mice exhibit shortened long bones, trabecular bone alterations and skeletal abnormalities in the growth plate. Additionally, we observed increased levels of inflammatory and oxidative markers in visceral organs and plasma. Our newly developed model of MPSIVA demonstrates clear and quantifiable signs of skeletal alterations, providing novel means of assessment of the safety and efficacy of innovative therapies, including hematopoietic stem and progenitor cell gene therapy, which has recently been shown to provide a beneficial effect on skeletal alterations in Hurler syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucopolysaccharidosis IVBone DiseasesAnimalsDisease Models, AnimalGlycosaminoglycansChondroitinsulfatasesKeratan SulfateChondroitin SulfatesCRISPR-Cas SystemsBiomarkersBone and BonesHumans

Stichwörter der Autor:innen

CRISPR-Cas9 disease modelingMPSIVAMucopolysaccharidosis IVAPreclinical modelSkeletal disease

Substanzen

GlycosaminoglycansChondroitinsulfatasesKeratan SulfateChondroitin SulfatesBiomarkers

Autor:innen und Institutionen

  • IRCSS San Raffaele Hospital-San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), 20132 Milan, Italy.
  • IMedical School, Vita-Salute San Raffaele University, 20132 Milan, Italy.
  • Good Laboratory Practice (GLP) Facility, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), 20132 Milan, Italy.
  • Endocrine and Osteometabolic Laboratory, Institute of Endocrine and Metabolic Sciences, IRCCS San Raffaele Hospital, 20132 Milan, Italy.
  • UniMoRe: Department of Life Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
  • Pathology Unit, IRCCS San Raffaele Hospital, 20132 Milan, Italy.

ORCID-Profile: Stefania Crippa

Förderung

  • Ministero dell'Istruzione, dell'Università e della Ricerca
  • NextGenerationEU
  • Else Kröner-Fresenius-Zentrum für Ernährungsmedizin
  • Fondazione Telethon
  • Ospedale San Raffaele

Zitieren

APA

Berti, M., Ceriotti, S., Santi, L., Alberti, G., Beretta, S., Degl'Innocenti, S., Ruatti, C., Savoia, E. O., Jofra-Hernandez, R., De Ponti, G., Bolamperti, S., Villa, I., Galeotti, F., Romano, A., Visigalli, I., Norata, R., Rocchi, M., Cristofori, P., Cossutta, M., …, & Crippa, S. (2026). Development and characterization of a model of mucopolysaccharidosis type IVA for evaluating therapies targeting bone disease. Disease Models & Mechanisms, 19(2). https://doi.org/10.1242/dmm.052540

Vancouver

Berti M, Ceriotti S, Santi L, Alberti G, Beretta S, Degl'Innocenti S, et al. Development and characterization of a model of mucopolysaccharidosis type IVA for evaluating therapies targeting bone disease. Disease Models & Mechanisms. 2026;19(2). doi:10.1242/dmm.052540

BibTeX
@article{Berti2026,
  author = {Berti, Margherita and Ceriotti, Selene and Santi, Ludovica and Alberti, Gaia and Beretta, Stefano and Degl'Innocenti, Sara and Ruatti, Cristina and Savoia, Evelyn Oliva and Jofra-Hernandez, Raisa and De Ponti, Giada and Bolamperti, Simona and Villa, Isabella and Galeotti, Fabio and Romano, Alessandro and Visigalli, Ilaria and Norata, Rossana and Rocchi, Martina and Cristofori, Patrizia and Cossutta, Matilde and Consiglieri, Giulia and Tucci, Francesca and Santorelli, Lucia and Grumati, Paolo and Ronfani, Lorenza and D'Adamo, Patrizia and Giustina, Andrea and Angelozzi, Marco and Settembre, Carmine and Mortellaro, Alessandra and Scala, Serena and Sanvito, Francesca and Volpi, Nicola and Aiuti, Alessandro and Bernardo, Maria Ester and Crippa, Stefania},
  title = {Development and characterization of a model of mucopolysaccharidosis type IVA for evaluating therapies targeting bone disease},
  journal = {Disease Models & Mechanisms},
  year = {2026},
  volume = {19},
  number = {2},
  doi = {10.1242/dmm.052540}
}
Kostenlos starten →